Payment of 2268 shares by Mark Smith of Smith Wesson subject to Rule 16b-3
| FNCHDelisted Stock | USD 8.51 0.19 2.18% |
Under 61% of Finch Therapeutics' investor base is looking to short. The analysis of overall sentiment of trading Finch Therapeutics Group pink sheet suggests that many investors are alarmed at this time. Finch Therapeutics' investing sentiment shows overall attitude of investors towards Finch Therapeutics Group.
Finch |
Filed transaction by Smith Wesson Brands Inc director. Payment of exercise price or tax liability by delivering or withholding securities
Read at macroaxis.com
Finch Therapeutics Fundamental Analysis
We analyze Finch Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Finch Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Finch Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Earnings Per Share
Earnings Per Share Comparative Analysis
Finch Therapeutics is currently under evaluation in earnings per share category among its peers. Earnings per Share (EPS) denotes the portion of a company's earnings that is allocated to each share of common stock. To calculate Earnings per Share investors will need to take a company's net income, subtract any dividends for preferred stock, and divide it by the number of average outstanding shares. EPS is usually presented in two different ways: basic and diluted. Fully diluted Earnings per Share takes into account effects of warrants, options, and convertible securities and is generally viewed by analysts as a more accurate measure.
Finch Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Finch Therapeutics pink sheet to make a market-neutral strategy. Peer analysis of Finch Therapeutics could also be used in its relative valuation, which is a method of valuing Finch Therapeutics by comparing valuation metrics with similar companies.
Peers
Finch Therapeutics Related Equities
| KPRX | Kiora Pharmaceuticals | 1.03 | ||||
| CELC | Celcuity LLC | 0.91 | ||||
| RNXT | RenovoRx | 0.72 | ||||
| XLO | Xilio Development | 0.99 | ||||
| QNRX | Quoin Pharmaceuticals | 1.49 | ||||
| IKNA | Ikena Oncology | 3.01 | ||||
| HOWL | Werewolf Therapeutics | 4.32 | ||||
| EWTX | Edgewise Therapeutics | 4.37 | ||||
| LGVN | Longeveron LLC | 4.52 | ||||
| REVB | Revelation Biosciences | 4.69 | ||||
| GLUE | Monte Rosa | 5.22 | ||||
| CCCC | C4 Therapeutics | 5.62 | ||||
| DSGN | Design Therapeutics | 6.18 | ||||
| NTRB | Nutriband | 8.44 | ||||
| VRAX | Virax Biolabs | 10.93 | ||||
| STOK | Stoke Therapeutics | 15.52 |
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.
Other Consideration for investing in Finch Pink Sheet
If you are still planning to invest in Finch Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Finch Therapeutics' history and understand the potential risks before investing.
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |